You are here: Industry Insights > CML

News List

1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib PR Newswire
December 10, 2024
Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data from a global study of its novel drug candidate, olverembatinib (HQP1351), in patients with heavily pretreated chronic myeloid leukemia (CML).
Access to Novartis treatment for Myeloid leukaemia patients pharmatimes
January 25, 2022
Novartis UK has announced that the MHRA has given a positive scientific opinion for the investigational treatment, asciminib
Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia prnasia
November 23, 2021
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC)...
Novartis' CML drug hits PhIII targets pharmatimes
August 26, 2020
Novartis' Phase III ASCEMBL study has met its primary goal showing that asciminib was superior to bosutinib in inducing a major molecular response (MMR) in patients with a certain from of chronic myeloid leukaemia (CML).
Dr Reddy’s Laboratories announces the launch of Invista (dasatinib) in India expresspharma
April 14, 2020
It is indicated for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.
Novartis continues to innovate in CML biospectrumasia
June 16, 2019
Novartis International AG / Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001).
BMS’ Sprycel secures European nod to treat Ph+ CML pharmaceutical-technology
July 12, 2018
Bristol-Myers Squibb (BMS) has secured approval from the European Commission (EC) for the use of its Sprycel (dasatinib) to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
Lawsuits Allege Safety Concern Over Novartis CML Drug Tasigna biospace
March 30, 2018
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
CML patients in England win access to Incyte’s Iclusig pharmatimes
May 03, 2017
Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine...